Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
We spoke to Jesús San Miguel, MD, PhD, of the University of Navarra, Pamplona, Spain, to discuss the importance of measurable residual disease (MRD) in the eradication of multiple myeloma (MM). This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.